Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge
Abstract
:1. Introduction
2. Methods
2.1. Measures
2.1.1. Outcome
2.1.2. Predictors
2.2. Statistical Analyses
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2020; Canadian Cancer Society: Toronto, ON, Canada, 2020. [Google Scholar]
- Fervaha, G.; Izard, J.P.; Tripp, D.A.; Rajan, S.; Leong, D.P.; Siemens, D.R. Depression and prostate cancer: A focused review for the clinician. Urol. Oncol. Semin. Orig. Investig. 2019, 37, 282–288. [Google Scholar] [CrossRef] [PubMed]
- Gillis, C.; Ilie, G.; Mason, R.; Bailly, G.; Lawen, J.; Bowes, D.; Patil, N.; Wilke, D.; Rutledge, R.; Bell, D.; et al. Personality Traits and Urinary Symptoms Are Associated with Mental Health Distress in Patients with a Diagnosis of Prostate Cancer. Curr. Oncol. 2021, 28, 2993–3002. [Google Scholar] [CrossRef] [PubMed]
- Ilie, G.; Rutledge, R.; Sweeney, E. Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer. Psycho-Oncology 2019, 29, 280–286. [Google Scholar] [CrossRef] [PubMed]
- Ilie, G.; White, J.; Mason, R.; Rendon, R.; Bailly, G.; Lawen, J.; Bowes, D.; Patil, N.; Wilke, D.; MacDonald, C.; et al. Current Mental Distress Among Men With a History of Radical Prostatectomy and Related Adverse Correlates. Am. J. Men’s Health 2020, 14. [Google Scholar] [CrossRef] [PubMed]
- Ilie, G.; Macdonald, M.; Bell, D.; Rendon, R.; Langille, G.; Bailly, G.; Mason, R.; Bowes, D.; Wilke, D.; Patil, N.; et al. An Examination of the Relationship between Mental Distress, Functional and Psychosocial Quality of Life Indicators in a Population Based Sample of Prostate Cancer Survivors Who Received Curative Treatment. Urol. Pract. 2020, 7, 384–390. [Google Scholar] [CrossRef]
- Ilie, G.; Rutledge, R.; Sweeney, E. An Examination of the Role of Socioeconomic Status in the Relationship between Depression and Prostate Cancer Survivorship in a Population-Based Sample of Men from Atlantic Canada. Oncology 2021, 99, 260–270. [Google Scholar] [CrossRef]
- Ilie, G.; Rutledge, R.; Sweeney, E. Post-Treatment Adverse Health Correlates among Prostate Cancer Survivors in a Sample of Men Residing in Atlantic Canada. Curr. Oncol. 2021, 28, 2812–2822. [Google Scholar] [CrossRef]
- Watts, S.; Leydon, G.M.; Birch, B.; Prescott, P.; Lai, L.; Eardley, S.; Lewith, G. Depression and anxiety in prostate cancer: A systematic review and meta-analysis of prevalence rates. BMJ Open 2014, 4, e003901. [Google Scholar] [CrossRef]
- Moodie, L.; Ilie, G.; Rutledge, R.; Andreou, P.; Kirkland, S. Assessment of Current Mental Health Status in a Population-Based Sample of Canadian Men With and Without a History of Prostate Cancer Diagnosis: An Analysis of the Canadian Longitudinal Study on Aging (CLSA). Front. Psychiatry 2020, 11, 1383. [Google Scholar] [CrossRef]
- Bradley, C.; Ilie, G.; MacDonald, C.; Massoeurs, L.; Vo, J.; Rutledge, R. Treatment regret, mental and physical health indicators of psychosocial well-being among prostate cancer survivors. Curr. Oncol. 2021. In print. [Google Scholar]
- Guercio, C.; Mehta, A. Predictors of Patient and Partner Satisfaction Following Radical Prostatectomy. Sex. Med. Rev. 2018, 6, 295–301. [Google Scholar] [CrossRef]
- Ilie, G. A prostate cancer quality of life pilot project testing the feasibility of PROs data collection using an on-line survey infrastructure throughout the Maritimes. In Interim Report, April 2018. Soillse Scientist Research Working Document Series No.1; ACCC: Halifax, NS, Canada, 2018. [Google Scholar]
- Kelley, S.; DeCourtney, C.; Thorsness, J. Development and evaluation of a support program for prostate cancer survivors in Alaska. Int. J. Circumpolar Health 2015, 74, 28605. [Google Scholar] [CrossRef]
- Fervaha, G.; Izard, J.P.; Tripp, D.A.; Aghel, N.; Shayegan, B.; Klotz, L.; Niazi, T.; Fradet, V.; Taussky, D.; Lavallée, L.T.; et al. Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Can. Urol. Assoc. J. 2020, 15, 181–186. [Google Scholar] [CrossRef]
- Brunckhorst, O.; Hashemi, S.; Martin, A.; George, G.; Van Hemelrijck, M.; Dasgupta, P.; Stewart, R.; Ahmed, K. Depression, anxiety, and suicidality in patients with prostate cancer: A systematic review and Meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2021, 24, 281–289. [Google Scholar] [CrossRef] [PubMed]
- Albertsen, P.C.; Hanley, J.A.; Fine, J. 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 2005, 293, 2095–2101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bredle, J.M.; Salsman, J.M.; Debb, S.M.; Arnold, B.J.; Cella, D. Spiritual Well-Being as a Component of Health Related Quality of Life: The Functional Assessment of Chronic Illness Therapy—Spiritual Well Being Scale (FACIT-Sp). Religions 2011, 2, 77–94. [Google Scholar] [CrossRef] [Green Version]
- Brady, M.J.; Peterman, A.H.; Fitchett, G.; Mo, M.; Cella, D. A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology 1999, 8, 417–428. [Google Scholar] [CrossRef]
- Rice, S.M.; Kealy, D.; Ogrodniczuk, J.S.; E Seidler, Z.; Denehy, L.; Oliffe, J.L. The Cost of Bottling It Up: Emotion Suppression as a Mediator in the Relationship Between Anger and Depression Among Men with Prostate Cancer. Cancer Manag. Res. 2020, 12, 1039–1046. [Google Scholar] [CrossRef] [Green Version]
- Garssen, B.; Uwland-Sikkema, N.F.; Visser, A. How Spirituality Helps Cancer Patients with the Adjustment to their Disease. J. Relig. Health 2015, 54, 1249–1265. [Google Scholar] [CrossRef]
- Garssen, B.; Visser, A.; Pool, G. Does Spirituality or Religion Positively Affect Mental Health? Meta-analysis of Longitudinal Studies. Int. J. Psychol. Relig. 2020, 31, 4–20. [Google Scholar] [CrossRef]
- Burns, S.M.; Mahalik, J.R. Physical health, self-reliance, and emotional control as moderators of the relationship between locus of control and mental health among men treated for prostate cancer. J. Behav. Med. 2006, 29, 561–572. [Google Scholar] [CrossRef] [PubMed]
- Roberts, K.J.; Lepore, S.J.; Helgeson, V. Social-cognitive correlates of adjustment to prostate cancer. Psycho-Oncology 2006, 15, 183–192. [Google Scholar] [CrossRef] [PubMed]
- Willener, R.; Hantikainen, V. Individual quality of life following radical prostatectomy in men with prostate cancer. Urolog. Nurs. 2005, 25, 88–90, 95–100. [Google Scholar]
- Kessler, R.C.; Andrews, G.; Colpe, L.J.; Hiripi, E.; Mroczek, D.K.; Normand, S.-L.; Walters, E.E.; Zaslavsky, A.M. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol. Med. 2002, 32, 959–976. [Google Scholar] [CrossRef] [PubMed]
- Kessler, R.C.; Barker, P.R.; Colpe, L.J.; Epstein, J.F.; Gfroerer, J.C.; Hiripi, E.; Howes, M.J.; Normand, S.-L.; Manderscheid, R.W.; Walters, E.E.; et al. Screening for Serious Mental Illness in the General Population. Arch. Gen. Psychiatry 2003, 60, 184–189. [Google Scholar] [CrossRef] [PubMed]
- Merson, F.; Newby, J.; Shires, A.; Millard, M.; Mahoney, A. The temporal stability of the Kessler Psychological Distress Scale. Aust. Psychol. 2021, 56, 38–45. [Google Scholar] [CrossRef]
- Sampasa-Kanyinga, H.; Zamorski, M.A.; Colman, I. The psychometric properties of the 10-item Kessler Psychological Distress Scale (K10) in Canadian military personnel. PLoS ONE 2018, 13, e0196562. [Google Scholar] [CrossRef] [Green Version]
- Cella, D.F.; Tulsky, D.S.; Gray, G.; Sarafian, B.; Linn, E.; Bonomi, A.; Silberman, M.; Yellen, S.B.; Winicour, P.; Brannon, J.; et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J. Clin. Oncol. 1993, 11, 570–579. [Google Scholar] [CrossRef]
- Esper, P.; Mo, F.; Chodak, G.; Sinner, M.; Cella, D.; Pienta, K. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology 1997, 50, 920–928. [Google Scholar] [CrossRef]
- Victorson, D.; Barocas, J.; Song, J.; Cella, D. Reliability across studies from the functional assessment of cancer therapy-general (FACT-G) and its subscales: A reliability generalization. Qual. Life Res. 2008, 17, 1137–1146. [Google Scholar] [CrossRef]
- Wong, C.K.H.; Choi, E.P.H.; Tsu, J.H.L.; Ho, B.S.H.; Ng, A.T.L.; Chin, W.Y.; Yiu, M.K. Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer. Qual. Life Res. 2015, 24, 2397–2402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Morita, S.; Aihara, O.; Tsujii, H.; Shimozuma, K.; Matsushima, E.; Noguchi, W.; Ohno, T. Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp) for Japanese patients with cancer. Support. Care Cancer 2004, 12, 240–245. [Google Scholar] [CrossRef] [PubMed]
- Barry, M.J.; Fowler, F.J.; O’Leary, M.P.; Bruskewitz, R.C.; Holtgrewe, H.L.; Mebust, W.K.; Cockett, A.T. Measurement Committee of the American Urological Association The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J. Urol. 2016, 197, S189–S197. [Google Scholar] [CrossRef] [PubMed]
- Lee, K.C.; Weiss, J.P. Diagnosis, Assessment and Examination. In Nocturia: Ethiology, Pathology, Risk Factors, Treatment, and Emerging Therapies; Academic Press: New York, NY, USA; pp. 41–69. [CrossRef]
- Johnson, M.E.; Zaorsky, N.G.; Martin, J.M.; Ruth, K.; Greenberg, R.E.; Uzzo, R.G.; Hayes, S.B.; Smaldone, M.C.; Kutikov, A.; Viterbo, R.; et al. Patient reported outcomes among treatment modalities for prostate cancer. Can. J. Urol. 2016, 23, 8535–8545. [Google Scholar]
- Nontakaew, K.; Kochakarn, W.; Kijvika, K.; Viseshsindh, W.; Silpakit, C. Reliability of a Thai version of the International Prostate Symptom Score (IPSS) for the Thai population. J. Med. Assoc. Thai. 2014, 97, 615–620. [Google Scholar]
- Van Buuren, S. Flexible Imputation of Missing Data; Chapman & Hall/CRC: London, UK, 2018. [Google Scholar]
- Sterne, J.A.; White, I.R.; Carlin, J.B.; Spratt, M.; Royston, P.; Kenward, M.G.; Wood, A.M.; Carpenter, J.R. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 2009, 338, 2393. [Google Scholar] [CrossRef]
- Alexis, O.; Worsley, A. An integrative review exploring black men of African and Caribbean backgrounds, their fears of prostate cancer and their attitudes towards screening. Health Educ. Res. 2018, 33, 155–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bokhour, B.G.; Clark, J.A.; Inui, T.S.; Silliman, R.A.; Talcott, J.A. Sexuality after treatment for early prostate cancer. J. General Intern. Med. 2004, 16, 649–655. [Google Scholar] [CrossRef]
- Maharaj, N.; Kazanjian, A. Exploring patient narratives of intimacy and sexuality among men with prostate cancer. Couns. Psychol. Q. 2021, 34, 163–182. [Google Scholar] [CrossRef]
- Hedestig, O.; Sandman, P.; Tomic, R.; Widmark, A. Living after radical prostatectomy for localized prostate cancer: A qualitative analysis of patient narratives. Acta Oncol. 2005, 44, 679–686. [Google Scholar] [CrossRef]
- Michaelson, M.D.; Cotter, S.E.; Gargollo, P.C.; Zietman, A.L.; Dahl, D.M.; Smith, M.R. Management of complications of prostate cancer treatment. CA A Cancer J. Clin. 2008, 58, 196–213. [Google Scholar] [CrossRef] [PubMed]
- Nolsøe, A.B.; Jensen, C.F.S.; Østergren, P.B.; Fode, M. Neglected side effects to curative prostate cancer treatments. Int. J. Impot. Res. 2021, 33, 428–438. [Google Scholar] [CrossRef] [PubMed]
- Cliff, A.M.; Macdonagh, R.P. Psychosocial morbidity in prostate cancer: II. A comparison of patients and partners. BJU Int. 2000, 86, 834–839. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ravi, P.; Karakiewicz, P.I.; Roghmann, F.; Gandaglia, G.; Choueiri, T.K.; Menon, M.; McKay, R.R.; Nguyen, P.L.; Sammon, J.D.; Sukumar, S.; et al. Mental health outcomes in elderly men with prostate cancer. Urol. Oncol. 2014, 32, 1333–1340. [Google Scholar] [CrossRef]
- Bellardita, L.; Valdagni, R.; van den Bergh, R.; Randsdorp, H.; Repetto, C.; Venderbos, L.D.; Lane, J.A.; Korfage, I.J. How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur. Urol. 2015, 67, 637–645. [Google Scholar] [CrossRef] [Green Version]
- Dahl, A.A.; Fosså, S.D.; Brennhovd, B.; Axcrona, K. The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism. Int. Urol. Nephrol. 2020, 53, 691–698. [Google Scholar] [CrossRef]
- Rottmann, N.; Dalton, S.O.; Christensen, J.; Frederiksen, K.; Johansen, C. Self-efficacy, adjustment style and well-being in breast cancer patients: A longitudinal study. Qual. Life Res. 2010, 19, 827–836. [Google Scholar] [CrossRef] [PubMed]
- Lazarus, R.; Folkman, S. Stress, Appraisal and Coping; Springer: New York, NY, USA, 1984. [Google Scholar]
- Pickles, T.; Ruether, J.D.; Weir, L.; Carlson, L.; Jakulj, F.; SCRN Communication Team. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007, 100, 544–551. [Google Scholar] [CrossRef] [PubMed]
- Traeger, L.; Penedo, F.J.; Gonzalez, J.S.; Dahn, J.R.; Lechner, S.C.; Schneiderman, N.; Antoni, M.H. Illness perceptions and emotional well-being in men treated for localized prostate cancer. J. Psychosom. Res. 2009, 67, 389–397. [Google Scholar] [CrossRef]
- Orom, H.; Biddle, C.; Underwood, W., 3rd; Nelson, C.J. Worse Urinary, Sexual and Bowel Function Cause Emotional Distress and Vice Versa in Men Treated for Prostate Cancer. J. Urol. 2018, 199, 1464–1469. [Google Scholar] [CrossRef]
- Boevé, L.; Hulshof, M.C.C.M.; Verhagen, P.C.M.S.; Twisk, J.W.R.; Witjes, W.P.J.; de Vries, P.; van Moorselaar, R.J.A.; van Andel, G.; Vis, A.N. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. Eur. Urol. 2021, 79, 188–197. [Google Scholar] [CrossRef] [PubMed]
- Bowie, J.V.; Dobson Sydnor, K.; Granot, M.; Pargament, K.I. Spirituality and Coping Among Survivors of Prostate Cancer. J. Psychosoc. Oncol. 2004, 22, 41–56. [Google Scholar] [CrossRef]
- Riley, B.B.; Perna, R.; Tate, D.G.; Forchheimer, M.; Anderson, C.; Luera, G. Types of spiritual well-being among persons with chronic illness: Their relation to various forms of quality of life. Arch Phys. Med. Rehabil. 1998, 79, 258–264. [Google Scholar] [CrossRef]
- Peterman, A.H.; Fitchett, G.; Brady, M.J.; Hernandez, L.; Cella, D. Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy-spiritual well-being scan (FACIT-Sp). Annu. Behav. Med. 2002, 24, 49–58. [Google Scholar] [CrossRef]
- Elkins, D.N.; Hedstrom, L.J.; Hughes, L.L.; Leaf, J.A.; Saunders, C. Toward a humanistic phenomenological spirituality. J. Humanist Psychol. 1998, 28, 5–18. [Google Scholar] [CrossRef]
- Pargament, K.I. The psychology of religion and spirituality? Yes and No. Int. J. Psychol. Relig. 1999, 9, 3–16. [Google Scholar] [CrossRef]
- Zavala, M.W.; Maliski, S.L.; Kwan, L.; Fink, A.; Litwin, M.S. Spirituality and quality of life in low-income men with metastatic prostate cancer. Psycho-Oncology 2009, 18, 753–761. [Google Scholar] [CrossRef]
- Balboni, T.A.; Vanderwerker, L.C.; Block, S.D.; Paulk, M.E.; Lathan, C.S.; Peteet, J.R.; Prigerson, H.G. Religiousness and spiritual support among advanced cancer patients and associations with end-of life treatment preferences and quality of life. J. Clin. Oncol. 2007, 25, 555–560. [Google Scholar] [CrossRef]
- Krupski, T.L.; Kwan, L.; Fink, A.; Sonn, G.A.; Maliski, S.; Litwin, M.S. Spirituality influences healthrelated quality of life in men with prostate cancer. Psycho-Oncology 2006, 15, 121–131. [Google Scholar] [CrossRef]
- Potosky, A.L.; Han, P.K.; Rowland, J.; Klabunde, C.N.; Smith, T.; Aziz, N.; Earle, C.; Ayanian, J.Z.; Ganz, P.A.; Stefanek, M. Differences between primary care physicians’ and oncologists’ knowledge, attitudes and practices regarding the care of cancer survivors. J. Gen. Int. Med. 2011, 26, 1403–1410. [Google Scholar] [CrossRef] [Green Version]
- Newport, D.J.; Nemeroff, C.B. Assessment and treatment of depression in the cancer patient. J. Psychosom. Res. 1998, 45, 215–237. [Google Scholar] [CrossRef]
- Ilie, G.; Mason, R.; Bell, D.; Bailly, G.; Rendon, R.A.; Mann, R.; Lawen, J.G.; Bowes, D.; Wilke, D.; Patil, N.; et al. Development and Initial Evaluation of a Multifaceted Intervention to Improve Mental Health and Quality of Life Among Prostate Cancer Survivors. Int. J. Ment. Health Addict. 2019, 18, 1067–1080. [Google Scholar] [CrossRef]
- Hua, A.; Sesto, M.E.; Zhang, X.; Wassenaar, T.R.; Tevaarwerk, A.J. Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice. J. Cancer Educ. 2019, 35, 249–255. [Google Scholar] [CrossRef] [PubMed]
- Song, L.; Guo, P.; Tan, X.; Chen, R.C.; Nielsen, M.E.; Birken, S.A.; Koontz, B.F.; Northouse, L.L.; Mayer, D.K. Enhancing survivorship care planning for patients with localized prostate cancer using a couple focused web-based, mHealth program: The Results of a pilot feasibility study. J. Cancer Surviv. 2021, 15, 99–108. [Google Scholar] [CrossRef]
- Streiner, D.L. Research Methods in Psychiatry: Breaking up is hard to do: The heartbreak of dichotomizing continuous data. Can. J. Psychiatry 2002, 47, 262–266. [Google Scholar] [CrossRef] [Green Version]
Variable | Sample Characteristics |
---|---|
Age (n, Mean (SD, range)) | 321, 68.55 (7.117, 47–88) |
Education (n, %) | |
Highschool or less | 42, 14.5% |
Bachelor or less | 166, 57.4% |
Graduate education | 81, 28.0% |
Currently in a relationship (n,%) | 291, 80.4% |
Retired or unemployed, (n,%) | 232, 72.3% |
Household income (n,%) | |
<50K | 73, 25.1% |
50K–100K | 130, 44.7% |
>100K | 88, 30.2% |
Survivorship time (months) from diagnosis (n, Mean, (SD)) | 316, 63.23 (57.73) |
Treatment modality (n,%) | |
Active surveillance | 90, 27.1% |
Surgery (alone or plus other forms of treatment) | 140, 42.2% |
Radiation or Hormone therapy alone, or both | 102, 30.7% |
Urinary tract symptoms, I-PSS, (n,%) | |
None to mild | 203, 62.1% |
Moderate or severe | 124, 37.9% |
Social/family well-being 1, FACT-P [n, Mean (SD, min, max score)] | 362, 20.02 (5.52, 0–28) |
Emotional well-being 1, FACT-P [n, Mean (SD, min, max score)] | 362, 19.98 (3.90, 1–24) |
Functional well-being 1, FACT-P, [n, Mean (SD, min, max score)] | 361, 20.92, (5.50, 0–28) |
Spiritual well-being 1, FACIT-Sp, [n, Mean (SD, min, max score)] | 359, 32.91, (9.36, 5–48) |
Predictors | Screening Negative for Mental Disorder (n = 239) OR (95% CI) | Screening Positive for Mental Disorder (n = 45) OR (95% CI) | Wald X2 |
---|---|---|---|
Urinary tract symptoms, I-PSS, % | X2(1) = 9.78 ** | ||
None to mild | 62.5% 1.0 Reference | 35.7% 1.0 Reference | |
Moderate or severe | 37.5% 1.0 Reference | 64.3% 3.00 (1.51–5.97) ** | |
Social/family well-being 1, FACT-P [Mean (SD)] | 21.31 (4.77) 1.0 Reference | 15.16 (6.19) 0.83 (0.78–0.88) *** | X2(1) = 34.46 *** |
Emotional well-being 1, FACT-P [Mean (SD)] | 21.06 (2.83) 1.0 Reference | 16.04 (4.51) 0.70 (0.63–0.78) *** | X2(1) = 42.85 *** |
Functional well-being 1, FACT-P, [Mean (SD)] | 22.29 (4.72) 1.0 Reference | 15.60 (5.40) 0.80 (0.74–0.85) *** | X2(1) = 40.41 *** |
Spiritual well-being 1, FACIT-Sp, [Mean (SD)] | 35.26 (8.16) 1.0 Reference | 22.73 (8.16) 0.84 (0.80–0.88) *** | X2(1) = 45.03 *** |
Treatment Modality, % | X2 (2) = 5.02 | ||
Active surveillance | 13.9% 1.0 Reference | 26.2% 2.97 (1.14–7.71) * | |
Surgery (alone or plus other forms of treatment) | 48.6% 1.0 Reference | 50.0% 1.62 (0.72-3.63) | |
Radiation or hormone therapy alone, or both | 37.5% 1.0 Reference | 23.8% 1.0 Reference | |
Age, [Mean (SD)] | 69.13 (6.82) 1.0 Reference | 66.49 (8.67) 0.95 (0.91–0.99) * | X2(1) = 5.01 * |
Survivorship time (months) from diagnosis, [Mean (SD)] | 66.46 (58.40) 1.0 Reference | 62.30 (55.45) 1.00 (0.99–1.01) | X2(1) = 0.19 |
Household income, % | X2(2) = 0.62 | ||
<CAD 50,000 | 23.4% 1.0 Reference | 22.0% 0.78 (0.32–1.93) | |
CAD 50,000–CAD 100,000 | 46.3% 1.0 Reference | 41.5% 0.74 (0.35–1.59) | |
>CAD 100,000 | 30.4% 1.0 Reference | 36.6% 1.0 Reference | |
Currently in a relationship, % | X2(1) = 0.25 | ||
No | 1.3% 1.0 Reference | 2.2% 1.79 (0.18–17.58) | |
Yes | 98.7% 1.0 Reference | 97.8% 1.0 Reference |
Predictors | Screening Negative for Mental Disorder (n = 239) 1.0 Reference | Screening Positive for Mental Disorder (n = 45) aOR (95% CI) a aORMI (95% CI) b | Wald X2 a Wald X2 b |
---|---|---|---|
X2(12) = 90.23 *** | |||
Urinary tract symptoms, I-PSS | |||
Moderate or severe vs. None to mild (Reference) | 1.0 Reference | 3.02 (1.10–8.32) * 3.27 (1.38–7.75) * | X2(1) = 4.56 * X2(1) = 7.27 * |
Social/family well-being 1, FACT-P | 1.0 Reference | 0.94 (0.83–1.05) 0.93 (0.84–1.03) | X2(1) = 0.94 X2(1) = 2.17 |
Emotional well-being 1, FACT-P | 1.0 Reference | 0.81 (0.69–0.96) * 0.87 (0.76–0.98) * | X2(1) = 5.86 * X2(1) = 4.52 * |
Functional well-being 1, FACT-P | 1.0 Reference | 1.00 (0.87–1.15) 1.02 (0.90–1.14) | X2(1) = 0.01 X2(1) = 0.06 |
Spiritual well-being 1, FACIT-Sp | 1.0 Reference | 0.88 (0.81–0.96) ** 0.92 (0.86–0.99) * | X2(1) = 8.80 ** X2(1) = 5.66 * |
Treatment Modality | X2(2) = 5.91 * X2(2) = 7.64 * | ||
Active surveillance vs. Radiation or Hormone therapy alone, or both (Reference) | 1.0 Reference | 5.87 (1.32–26.13) * 4.95 (1.55–15.82) * | |
Surgery (alone or plus other forms of treatment) vs. Radiation or Hormone therapy alone, or both (Reference) | 1.0 Reference | 4.21 (1.07–16.51) * 3.95 (1.15–13.63) * | |
Age | 1.0 Reference | 1.01 (0.94–1.08) 1.02 (0.96–1.08) | X2(1) = 0.06 X2(1) = 0.45 |
Survivorship time (months) from diagnosis | 1.0 Reference | 1.00 (0.99–1.01) 1.00 (0.99–1.01) | X2(1) = 0.69 X2(1) = 0.40 |
Household income | X2(2) = 4.78 X2(2) = 4.23 | ||
<CAD 50,000 vs. >CAD 100,000 (Reference) | 1.0 Reference | 0.27 (0.07–1.07) 0.35 (0.11–1.09) | |
CAD 50,000–CAD 100,000 vs. >CAD 100,000 (Reference) | 1.0 Reference | 0.32 (0.09–1.04) 0.43 (0.17–1.13) | |
Currently in a relationship | X2(1) = 0.70 X2(1) = 2.84 | ||
No vs. Yes (Reference) | 1.0 Reference | 0.24 (0.01–6.78) 0.30 (0.07–1.22) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Massoeurs, L.; Ilie, G.; Lawen, T.; MacDonald, C.; Bradley, C.; Vo, J.D.C.-T.; Rutledge, R.D.H. Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge. Curr. Oncol. 2021, 28, 3918-3931. https://doi.org/10.3390/curroncol28050334
Massoeurs L, Ilie G, Lawen T, MacDonald C, Bradley C, Vo JDC-T, Rutledge RDH. Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge. Current Oncology. 2021; 28(5):3918-3931. https://doi.org/10.3390/curroncol28050334
Chicago/Turabian StyleMassoeurs, Lia, Gabriela Ilie, Tarek Lawen, Cody MacDonald, Cassidy Bradley, Jasmine Dang Cam-Tu Vo, and Robert David Harold Rutledge. 2021. "Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge" Current Oncology 28, no. 5: 3918-3931. https://doi.org/10.3390/curroncol28050334
APA StyleMassoeurs, L., Ilie, G., Lawen, T., MacDonald, C., Bradley, C., Vo, J. D. C. -T., & Rutledge, R. D. H. (2021). Psychosocial and Functional Predictors of Mental Disorder among Prostate Cancer Survivors: Informing Survivorship Care Programs with Evidence-Based Knowledge. Current Oncology, 28(5), 3918-3931. https://doi.org/10.3390/curroncol28050334